Additionally, there is a growing number of cancers thought to be driven by the mutational inactivation or alteration of a metabolic enzyme such as succinate dehydrogenase (SDH; Bardella et al, 2011; Thompson, 2009), fumarate hydratase (FH; Tomlinson et al, 2002) or isocitrate dehydrogenase (IDH; Waitkus et al, 2018), and there is an emerging and growing understanding of the impact of metabolic rewiring on the resistant and sensitivity of a cancer to common drugs (Zaal & Berkers, 2018; Desbats et al, 2020). This evidence concerns the gene IDH3A and cancer.